Fareeda Hosein

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · JAMA Oncology · 2019 · 632 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean-Jacques Grob et al. · European Journal of Cancer · 2019 · 180 citations

Medicine, Oncology, Immunotherapy +15

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Paolo A. Ascierto, Michele Del Vecchio, Andrzej Maćkiewicz et al. · Journal for ImmunoTherapy of Cancer · 2020 · 68 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma

Rui Wang, Xiao Shao, Junying Zheng et al. · Clinical Pharmacology & Therapeutics · 2019 · 30 citations

Medicine, Immunology, Oncology +17

Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.

Alexander Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · Journal of Clinical Oncology · 2019 · 26 citations

Medicine, Oncology, Pharmacotherapy +17